A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

N/ACompletedNCT00203086

Teva Branded Pharmaceutical Products R&D, Inc.30 enrolled

Overview

It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Relapsing Remitting Multiple Sclerosis

Eligibility

Sex: ALLMin age: 20 YearsMax age: 57 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participation \& completion of the NC-100 Clinical Trial. * Able and willing to sign an Informed Consent. Exclusion Criteria: none

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.